Non-competitive AMPA receptor antagonist (IC50
= 2.5 μ
M). Displays broad spectrum anticonvulsive activity and neuroprotective effects in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
New non competitive AMPA antagonists.
Abraham et al.
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Bibbiani et al.
Research on new AMPA antagonists of 2,3-benzodiazepine type.